TVM Capital Life Science

Montreal, QC
SeedSeries AGrowthRaiseTheNorth verification research (2026-09)

Investment Thesis

TVM Capital Life Science deploys a dual-pronged transatlantic strategy: financing innovative early-stage therapeutics through single-asset companies leveraging a strategic partnership with Eli Lilly, and investing in differentiated commercial-stage medtech, diagnostics, digital health, and late-stage therapeutics with clear exit strategies. The fund prioritizes assets with potential to transform medical practice and bring breakthrough therapies to patients while maximizing venture returns.

Focus Areas

Investment Stage
SeedSeries AGrowth
Sectors
TherapeuticsMedTechDiagnosticsLife Sciences

Investment Signals

Check SizeC$32.9M
GeographyGlobal
ProvincesQC
RoleBoth
Impact MandateYes
Business ModelsB2B, deep-tech, hardware, IP-licensing
Won't Invest Insoftware

Sample Portfolio Companies

Kent Imaging
Vektor Medical
CSA Medical
leon nanodrugs GmbH
AL-S Pharma AG
Centogene AG
Spepharm Holdings BV
Smart Reporting GmbH
Acer Therapeutics
Argos Therapeutics
Horizon Pharma Inc.
Bioxell SA

AUM & Sources

N/A
Assets under management (estimated)
Sources
No public sources found.
Raising from Canadian VCs?Get AI-matched to your top investors in seconds.
Find My Investors →

Similar Funds

BDC Life Sciences Venture Fund
Canada
SeedSeries A
Commercialization at UHN
Toronto, ON
Pre-SeedSeed
UCeed Health Fund
Calgary, AB
Pre-SeedSeed
adMare BioInnovations
Vancouver, BC
SeedSeries A

See incorrect information?

Help us keep this directory accurate and up to date.